Personal Products & Services
Compare Stocks
4 / 10Stock Comparison
EJH vs RGS vs ANGI vs SKIN
Revenue, margins, valuation, and 5-year total return — side by side.
Personal Products & Services
Internet Content & Information
Household & Personal Products
EJH vs RGS vs ANGI vs SKIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Personal Products & Services | Personal Products & Services | Internet Content & Information | Household & Personal Products |
| Market Cap | $5M | $68M | $210M | $118M |
| Revenue (TTM) | $102M | $233M | $1.02B | $296M |
| Net Income (TTM) | $-12M | $114M | $20M | $-6M |
| Gross Margin | 22.6% | 47.6% | 91.1% | 64.9% |
| Operating Margin | -13.3% | 10.5% | 4.8% | -3.6% |
| Forward P/E | — | 0.6x | 6.1x | — |
| Total Debt | $1M | $351M | $498M | $379M |
| Cash & Equiv. | $173M | $35M | $304M | $233M |
EJH vs RGS vs ANGI vs SKIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 21 | May 26 | Return |
|---|---|---|---|
| E-Home Household Se… (EJH) | 100 | 0.0 | -100.0% |
| Regis Corporation (RGS) | 100 | 15.3 | -84.7% |
| Angi Inc. (ANGI) | 100 | 3.7 | -96.3% |
| The Beauty Health C… (SKIN) | 100 | 6.4 | -93.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EJH vs RGS vs ANGI vs SKIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EJH is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 1 yrs, beta 0.82
- Rev growth -2.1%, EPS growth 97.4%, 3Y rev CAGR -8.1%
- Lower volatility, beta 0.82, Low D/E 0.5%, current ratio 24.58x
- Beta 0.82, current ratio 24.58x
RGS carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -89.7% 10Y total return vs SKIN's -91.6%
- 3.5% revenue growth vs ANGI's -13.0%
- Lower P/E (0.6x vs 6.1x)
- 48.9% margin vs EJH's -11.6%
ANGI plays a supporting role in this comparison — it may shine differently against other peers.
SKIN lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.5% revenue growth vs ANGI's -13.0% | |
| Value | Lower P/E (0.6x vs 6.1x) | |
| Quality / Margins | 48.9% margin vs EJH's -11.6% | |
| Stability / Safety | Beta 0.79 vs SKIN's 2.00, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +49.9% vs EJH's -98.5% | |
| Efficiency (ROA) | 19.4% ROA vs EJH's -4.4%, ROIC 3.2% vs -7.7% |
EJH vs RGS vs ANGI vs SKIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
EJH vs RGS vs ANGI vs SKIN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
RGS leads in 3 of 6 categories
EJH leads 0 • ANGI leads 0 • SKIN leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RGS leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ANGI is the larger business by revenue, generating $1.0B annually — 10.0x EJH's $102M. RGS is the more profitable business, keeping 48.9% of every revenue dollar as net income compared to EJH's -11.6%. On growth, RGS holds the edge at +22.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $102M | $233M | $1.0B | $296M |
| EBITDAEarnings before interest/tax | -$12M | $29M | $86M | $9M |
| Net IncomeAfter-tax profit | -$12M | $114M | $20M | -$6M |
| Free Cash FlowCash after capex | -$4M | $15M | $26M | $29M |
| Gross MarginGross profit ÷ Revenue | +22.6% | +47.6% | +91.1% | +64.9% |
| Operating MarginEBIT ÷ Revenue | -13.3% | +10.5% | +4.8% | -3.6% |
| Net MarginNet income ÷ Revenue | -11.6% | +48.9% | +1.9% | -2.0% |
| FCF MarginFCF ÷ Revenue | -4.1% | +6.4% | +2.5% | +9.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.3% | +22.3% | -3.2% | -6.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -77.1% | -94.1% | -163.3% | +38.0% |
Valuation Metrics
Evenly matched — EJH and SKIN each lead in 2 of 5 comparable metrics.
Valuation Metrics
At 0.6x trailing earnings, RGS trades at a 89% valuation discount to ANGI's 5.6x P/E. On an enterprise value basis, ANGI's 3.2x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $5M | $68M | $210M | $118M |
| Enterprise ValueMkt cap + debt − cash | -$167M | $384M | $404M | $264M |
| Trailing P/EPrice ÷ TTM EPS | -1.19x | 0.64x | 5.57x | -5.69x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 6.10x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 16.75x | 3.22x | 7331.15x |
| Price / SalesMarket cap ÷ Revenue | 0.10x | 0.32x | 0.20x | 0.39x |
| Price / BookPrice ÷ Book value/share | 0.02x | 0.40x | 0.26x | 2.02x |
| Price / FCFMarket cap ÷ FCF | — | 5.48x | 4.62x | 3.17x |
Profitability & Efficiency
Evenly matched — EJH and ANGI each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
RGS delivers a 60.4% return on equity — every $100 of shareholder capital generates $60 in annual profit, vs $-9 for SKIN. EJH carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs EJH's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | -4.6% | +60.4% | +2.1% | -9.4% |
| ROA (TTM)Return on assets | -4.4% | +19.4% | +1.2% | -1.2% |
| ROICReturn on invested capital | -7.7% | +3.2% | +5.0% | -6.8% |
| ROCEReturn on capital employed | -3.8% | +3.9% | +5.1% | -4.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.01x | 1.89x | 0.54x | 6.20x |
| Net DebtTotal debt minus cash | -$172M | $316M | $194M | $146M |
| Cash & Equiv.Liquid assets | $173M | $35M | $304M | $233M |
| Total DebtShort + long-term debt | $1M | $351M | $498M | $379M |
| Interest CoverageEBIT ÷ Interest expense | -394.47x | 1.31x | 5.38x | 0.81x |
Total Returns (Dividends Reinvested)
RGS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RGS five years ago would be worth $1,447 today (with dividends reinvested), compared to $0 for EJH. Over the past 12 months, RGS leads with a +49.9% total return vs EJH's -98.5%. The 3-year compound annual growth rate (CAGR) favors RGS at 10.8% vs EJH's -98.0% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -92.5% | +4.7% | -58.6% | -35.0% |
| 1-Year ReturnPast 12 months | -98.5% | +49.9% | -65.4% | -35.9% |
| 3-Year ReturnCumulative with dividends | -100.0% | +35.9% | -79.5% | -91.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -85.5% | -96.1% | -92.9% |
| 10-Year ReturnCumulative with dividends | -100.0% | -89.7% | -94.1% | -91.6% |
| CAGR (3Y)Annualised 3-year return | -98.0% | +10.8% | -41.1% | -56.4% |
Risk & Volatility
RGS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RGS is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than SKIN's 2.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RGS currently trades 88.9% from its 52-week high vs EJH's 0.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 0.79x | 1.85x | 2.00x |
| 52-Week HighHighest price in past year | $311.25 | $31.50 | $19.42 | $2.69 |
| 52-Week LowLowest price in past year | $0.82 | $17.50 | $4.53 | $0.76 |
| % of 52W HighCurrent price vs 52-week peak | +0.5% | +88.9% | +27.0% | +33.8% |
| RSI (14)Momentum oscillator 0–100 | 25.0 | 56.3 | 26.1 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 87K | 9K | 1.2M | 760K |
Analyst Outlook
Evenly matched — EJH and ANGI each lead in 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: ANGI as "Hold", SKIN as "Hold". Consensus price targets imply 143.3% upside for ANGI (target: $13) vs 42.9% for SKIN (target: $1).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Hold | Hold |
| Price TargetConsensus 12-month target | — | — | $12.75 | $1.30 |
| # AnalystsCovering analysts | — | — | 54 | 13 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 1 | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +70.7% | 0.0% |
RGS leads in 3 of 6 categories — strongest in Income & Cash Flow and Total Returns. 3 categories are tied.
EJH vs RGS vs ANGI vs SKIN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EJH or RGS or ANGI or SKIN a better buy right now?
For growth investors, Regis Corporation (RGS) is the stronger pick with 3.
5% revenue growth year-over-year, versus -13. 0% for Angi Inc. (ANGI). Regis Corporation (RGS) offers the better valuation at 0. 6x trailing P/E, making it the more compelling value choice. Analysts rate Angi Inc. (ANGI) a "Hold" — based on 54 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EJH or RGS or ANGI or SKIN?
On trailing P/E, Regis Corporation (RGS) is the cheapest at 0.
6x versus Angi Inc. at 5. 6x.
03Which is the better long-term investment — EJH or RGS or ANGI or SKIN?
Over the past 5 years, Regis Corporation (RGS) delivered a total return of -85.
5%, compared to -100. 0% for E-Home Household Service Holdings Limited (EJH). Over 10 years, the gap is even starker: RGS returned -89. 7% versus EJH's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EJH or RGS or ANGI or SKIN?
By beta (market sensitivity over 5 years), Regis Corporation (RGS) is the lower-risk stock at 0.
79β versus The Beauty Health Company's 2. 00β — meaning SKIN is approximately 154% more volatile than RGS relative to the S&P 500. On balance sheet safety, E-Home Household Service Holdings Limited (EJH) carries a lower debt/equity ratio of 1% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
05Which is growing faster — EJH or RGS or ANGI or SKIN?
By revenue growth (latest reported year), Regis Corporation (RGS) is pulling ahead at 3.
5% versus -13. 0% for Angi Inc. (ANGI). On earnings-per-share growth, the picture is similar: E-Home Household Service Holdings Limited grew EPS 97. 4% year-over-year, compared to 13. 9% for Regis Corporation. Over a 3-year CAGR, SKIN leads at -6. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EJH or RGS or ANGI or SKIN?
Regis Corporation (RGS) is the more profitable company, earning 58.
8% net margin versus -7. 6% for E-Home Household Service Holdings Limited — meaning it keeps 58. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RGS leads at 9. 5% versus -16. 7% for EJH. At the gross margin level — before operating expenses — ANGI leads at 90. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EJH or RGS or ANGI or SKIN more undervalued right now?
Analyst consensus price targets imply the most upside for ANGI: 143.
3% to $12. 75.
08Which pays a better dividend — EJH or RGS or ANGI or SKIN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is EJH or RGS or ANGI or SKIN better for a retirement portfolio?
For long-horizon retirement investors, Regis Corporation (RGS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
79)). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RGS: -89. 7%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EJH and RGS and ANGI and SKIN?
These companies operate in different sectors (EJH (Consumer Cyclical) and RGS (Consumer Cyclical) and ANGI (Communication Services) and SKIN (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: EJH is a small-cap quality compounder stock; RGS is a small-cap deep-value stock; ANGI is a small-cap deep-value stock; SKIN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.